Analysis of Phase Ⅲ Randomized Trial of Conventional Irradiaton Versus Hyperfractionated Irradiation with Late Course Concomitant Boost in Nasopharyngeal Carcinoma

潘自强,章真,何霞云,郭小毛,林原,何少琴,刘泰福
DOI: https://doi.org/10.3969/j.issn.1007-3639.2005.01.013
2005-01-01
Abstract:Purpose:To compare the treatment result and acu te toxicity of hyperfractionated radiation therapy with late course concomitant boost (HFLB) to conventional radiation regimen (CR). Methods:From March 1998 to August 2001, 163 patients with poorl y differentiated squamous cell carcinoma of nasopharynx were enrolled into this study. Eighty-one patients were randomized to HFLB group, being treated with 1. 2 Gy/F Bid (with interval of not less than 6 hours) to 48 Gy/40F/4weeks followed by 1.5 Gy/F Bid to a total dose of 78 Gy/60 F in 6 weeks. 82 patients received conventional radiotherapy (CR) with total dose of 70 Gy/35fractions in 7 weeks. Results:Median follow-up was 37 months (19-59 months). Two an d 4- year local control rates were 94.7%, 87.9% and 89.9%, 79.2% in HFLB group and CR group respectively (P= 0.1627 ); two and 4- year disease-free sur vival rates were 81.6%, 71.7% and 83.8%, 64.7% in HFLB group and CR group respec tively (P=0.5438); two and 4- year overall survival rate were 95.6%, 88.2% and 96.2%, 79.2% in HFLB group and CR group respectively (P=0.5424). Grade I II mucositis were more frequently observed in the HFLB group compared to the CR group(42% vs 15.9%), while the frequency of grade IV mucositis were similar (6% vs 5%). Conclusions:Compared to the conventional radiotherapy, the hype rfractionated radiotherapy with late course concomitant boost showed a trend tow ards a better local control rate with an increased severity of acute mucositis. The overall survival was similar in both groups.
What problem does this paper attempt to address?